Connor, Clark & Lunn Investment Management Ltd. Fulcrum Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 217,749 shares of FULC stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
217,749
Previous 367,594
40.76%
Holding current value
$1.44 Million
Previous $1.73 Million
63.69%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding FULC
# of Institutions
121Shares Held
51.9MCall Options Held
48.9KPut Options Held
13.8K-
Ra Capital Management, L.P. Boston, MA10.2MShares$67.7 Million0.61% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$34.8 Million3.64% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.07MShares$33.5 Million0.64% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.82MShares$31.9 Million0.63% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$31.8 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $344M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...